{"nctId":"NCT00449176","briefTitle":"A Study to Evaluate the Effectiveness and Safety of Tapentadol (CG5503) Extended Release (ER) in Patients With Moderate to Severe Chronic Low Back Pain","startDateStruct":{"date":"2007-02"},"conditions":["Low Back Pain"],"count":981,"armGroups":[{"label":"001","type":"EXPERIMENTAL","interventionNames":["Drug: tapentadol (CG5503) ER"]},{"label":"002","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: oxycodone CR"]},{"label":"003","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: placebo"]}],"interventions":[{"name":"tapentadol (CG5503) ER","otherNames":[]},{"name":"oxycodone CR","otherNames":[]},{"name":"placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Men and non-pregnant, non-lactating women having a diagnosis of Lower Back Pain (LBP) of non-malignant origin present for at least 3 months\n* Patients taking analgesic medications for at least 3 months prior to screening and/or dissatisfied with their current therapy\n* Patients requiring opioid treatment must be taking daily doses of opioid-based analgesic, equivalent to \\< 160 mg of oral morphine\n* Baseline score of =5 on an 11-point numerical rater scale, calculated as the average pain intensity during the last 3 days prior to randomization.\n\nExclusion Criteria:\n\n* History of alcohol and/or drug abuse in Investigator's judgement\n* History of significant liver insufficiency\n* chronic hepatitis B or C, or HIV, presence of active hepatitis B or C within the past 3 months\n* Life-long history of seizure disorder or epilepsy\n* History of malignancy within past 2 years, with exception of basal cell carcinoma that has been successfully treated\n* Uncontrolled hypertension\n* Patients with severely impaired renal function\n* Patients with moderate to severly impaired hepatic function or with laboratory values reflecting inadequate hepatic function","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change From Baseline of the Average Pain Intensity Based on a 11-point Numerical Rating Scale (NRS) Over the Last Week of the Maintenance Period at Week 12.","description":"For this twice daily pain assessment, the subjects were to indicate the level of pain experienced over the previous 12 hours on an 11-point Numerical Rating Scale (NRS) where a score of 0 indicated \"no pain\" and a score of 10 indicated \"pain as bad as you can imagine\".","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.9","spread":"2.66"},{"groupId":"OG001","value":"-2.9","spread":"2.52"},{"groupId":"OG002","value":"-2.1","spread":"2.33"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Brief Pain Inventory (BPI) Total Pain Score Over the Last Week of the Maintenance Period at Week 12.","description":"Total pain score where zero equals \"no pain\" to ten equals \"pain as bad as you can imagine\" from 12 week endpoint vs baseline.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.3","spread":"2.25"},{"groupId":"OG001","value":"-2.1","spread":"2.35"},{"groupId":"OG002","value":"-1.6","spread":"2.11"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Sleep Latency Time in Hours Over the Last Week of the Maintenance Period at Week 12.","description":"A Sleep Questionnaire addressed the following question: \"How long after bedtime/lights out did you fall asleep last night (hours)?\" 12 week endpoint-mean changes from baseline at endpoint for sleep latency. Decrease in time(hours) indicates improvement.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.2","spread":"3.08"},{"groupId":"OG001","value":"-0.2","spread":"2.32"},{"groupId":"OG002","value":"-0.1","spread":"2.43"}]}]}]},{"type":"SECONDARY","title":"Percentage of Patients Who Reported Very Much Improved or Much Improved From Baseline in Patient Global Impression of Change Over the Last Week of the Maintenance Period at Week 12","description":"Ordinal measure indicating change from start of treatment (On a scale of 7 = Very much Worse to 1 = very much improved)","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"55.5","spread":null},{"groupId":"OG001","value":"60","spread":null},{"groupId":"OG002","value":"32.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Treatment Discontinuation Due to Lack of Efficacy","description":"The number of participants who discontinued due to lack of efficacy from baseline to endpoint","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"18","spread":null},{"groupId":"OG001","value":"9","spread":null},{"groupId":"OG002","value":"64","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in EuroQol-5Â® (EQ-5D) Health Status Index to Week 12","description":"Change from baseline to end point in EuroQol-5 Dimension Questionnaire. A higher score indicates an improvement in health in the Health Status Index. The EuroQol-5 is a five dimensional health state classification. Each dimension is assessed on a 3-point ordinal scale (1=no problems, 2=some problems, 3=extreme problems). The responses to the five EQ-5D dimensions were scored using a utility-weighted algorithm to derive an EQ-5D health status index score between 0 to 1, with 1.00 indicating \"full health\" and 0 representing dead.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.2","spread":"0.3"},{"groupId":"OG001","value":"0.2","spread":"0.33"},{"groupId":"OG002","value":"0.1","spread":"0.33"}]}]}]},{"type":"SECONDARY","title":"Responder Analysis 50% Improvement","description":"Defined by the proportion of subjects achieving at least 50% improvement from baseline in the primary endpoint of change from baseline of the average pain intensity based on the 11-point Numerical Rating Scale (NRS) at week 12. The subjects were to indicate the level of pain experienced over the previous 12 hours on an 11-point NRS where a score of 0 indicated \"no pain\" and a score of 10 indicated \"pain as bad as you can imagine\".","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"27.0","spread":null},{"groupId":"OG001","value":"23.3","spread":null},{"groupId":"OG002","value":"18.9","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":8},"commonTop":["Nausea","Headache","Constipation","Dizziness","Somnolence"]}}}